12:00 AM
 | 
May 12, 2014
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Rexahn preclinical data

In mouse xenograft models of cancer, RX-21101 completely inhibited tumor growth, enhanced tumor regression and improved survival without significant changes in body weight compared to IV docetaxel....

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >